Kbc Group Nv Adaptimmune Therapeutics PLC Transaction History

Kbc Group Nv

$33.1 Billion
Q3 2024

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 03, 2022	SELL	$3.5 - $5.68 $160,650 - $260,712	-45,900 Closed	0 $0
Q3 2021 Nov 10, 2021	BUY	$3.44 - $6.37 $68,800 - $127,400	20,000 Added 77.22%	45,900 $237,000
Q2 2021 Aug 11, 2021	BUY	$3.86 - $5.78 $73,340 - $109,820	19,000 Added 275.36%	25,900 $110,000
Q1 2021 Apr 26, 2021	BUY	$4.9 - $6.83 $14,700 - $20,490	3,000 Added 76.92%	6,900 $37,000
Q3 2020 Oct 28, 2020	SELL	$7.66 - $10.78 $15,320 - $21,560	-2,000 Reduced 33.9%	3,900 $31,000
Q4 2019 Feb 11, 2020	BUY	$0.72 - $1.43 $4,125 - $8,193	5,730 Added 3370.59%	5,900 $7,000
Q3 2019 Nov 07, 2019	SELL	$1.43 - $3.81 $2,473 - $6,591	-1,730 Reduced 91.05%	170 $0
Q2 2019 Dec 03, 2019	BUY	$3.23 - $5.41 $6,137 - $10,279	1,900 New	1,900 $8,000
Q2 2019 Jul 30, 2019	SELL	$3.23 - $5.41 $6,137 - $10,279	-1,900 Closed	0 $0
Q1 2019 Dec 03, 2019	BUY	$3.63 - $6.06 $6,897 - $11,514	1,900 New	1,900 $8,000
Q1 2019 May 10, 2019	SELL	$3.63 - $6.06 $3,448 - $5,757	-950 Closed	0 $0
Q4 2018 Dec 03, 2019	BUY	$3.76 - $14.16 $3,572 - $13,452	950 New	950 $5,000
Q4 2018 Jan 31, 2019	SELL	$3.76 - $14.16 $3,572 - $13,452	-950 Closed	0 $0
Q3 2018 Dec 03, 2019	BUY	$8.27 - $13.56 $7,856 - $12,882	950 New	950 $13,000
Q3 2018 Nov 14, 2018	SELL	$8.27 - $13.56 $7,856 - $12,882	-950 Closed	0 $0
Q2 2018 Dec 03, 2019	BUY	$10.42 - $13.74 $9,899 - $13,053	950 New	950 $11,000
Q2 2018 Aug 03, 2018	SELL	$10.42 - $13.74 $9,899 - $13,053	-950 Closed	0 $0
Q1 2018 Dec 03, 2019	BUY	$7.1 - $11.56 $6,745 - $10,982	950 New	950 $11,000
Q1 2018 May 09, 2018	SELL	$7.1 - $11.56 $6,745 - $10,982	-950 Closed	0 $0
Q4 2017 Dec 03, 2019	BUY	$6.68 - $8.74 $6,346 - $8,303	950	950 $6,000

Others Institutions Holding ADAP

# of Institutions

Shares Held

150M

Call Options Held

60.8K

Put Options Held

5.8K

Matrix Capital Management Company, LP Waltham, MA

37.7M
Shares

$26.4 Million
1.71% of portfolio
Eco R1 Capital, LLC San Francisco, CA

27.4M
Shares

$19.2 Million
1.13% of portfolio
Nea Management Company, LLC Timonium, MD

17.1M
Shares

$12 Million
1.24% of portfolio
Baillie Gifford & CO

16.8M
Shares

$11.7 Million
0.01% of portfolio
Long Focus Capital Management, LLC San Juan, PR

13.3M
Shares

$9.31 Million
0.46% of portfolio

View Full List

About Adaptimmune Therapeutics PLC

Ticker ADAP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 163,370,000
Market Cap $114M
Description
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4...

More about ADAP

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Kbc Group Nv, based on Form 13F filings with the SEC.

News

Stay updated on Kbc Group Nv with notifications on news.

Account